Поиск путей индивидуализации лекарственного лечения больных колоректальным раком препаратами фторпиримидиного ряда
Диссертация
Несмотря на имеющиеся успехи при лечении больных КРР, современная химиотерапия вообще, и с применением фторпиримидинов в частности, обладает рядом недостатков. Главным из них является эмпиричность назначений различных комбинаций цитостатиков. Как правило, выбор схемы лечения основывается на достаточно косвенных показателях, таких как общее состояние пациента, клиническая картина заболевания… Читать ещё >
Список литературы
- Аксель Е.М., Ушакова Т. И. Статистика заболеваемости и смертности от рака ободочной и прямой кишки. В кн.: «Новое в терапии колоректального рака» под ред. Переводчиковой Н. И., М., 2001.
- Гарин A.M. Антиметаболиты // М. 1998.
- Гарин A.M. Место и значение антиметаболитов в химиотерапии злокачественных опухолей. М., — 2000. — 56с.
- Гарин A.M. Молекулярно-биологические мишени современной химиотерапии колоректального рака. В кн. «Новое в терапии колоректального рака» под ред. Переводчиковой H.H., 2001- 105−109.
- Гарин A.M. Химиотерапия диссеминированного рака ободочной кишки, очередность назначения цитостатиков // Практ. Онкология. 2000. — 1. — с. 27−30.
- Гарин A.M., Базин И. С. Злокачественные опухоли пищеварительной системы. М., — 2003. — 256с.
- Гершанович М.Л., Филатов В. А., Акимов М. А. и др. Введение в фармакотерапию злокачественных опухолей. СПб. — 1999.
- Давыдов М.И., Аксель Е. М. Злокачественные новообразования в России и странах СНГ.-М., 2004.-с. 101.
- Злокачественные новообразования в России в 1999 году (заболеваемость и смертность) // Под ред. В. И. Чиссова, В. В. Старинского. М., 2000.
- Злокачественные новообразования в Санкт-Петербурге в 1996 году (заболеваемость, смертность, летальность, выживаемость) // Под ред. проф. В. М. Мерабишвили. СПб., 1999.
- Имянитов E.H. Клинико-молекулярные аспекты колоректального рака: этиопатогенез, профилактика, индивидуализация лечения // Практическая онкология. 2005. — 6(2). — с. 65−70.
- Мерабишвили В.М., Дятченко О. Т., Цветкова T.JI. и др. Смертность населения Санкт-Петербурга от злокачественных опухолей // Материалымеждународного симпозиума. — Санкт-Петербург, 14−17.05. — СПб., 1996.-с. 76−78.
- Моисеенко В.М. Почему не уменьшаются показатели выживаемости у больных диссеминированными опухолями? В кн. «Лекции по фундаментальной и клинической онкологии» под ред. Моисеенко В. М., Урманчеевой А. Ф., Хансона К. П. 2004. — с. 168−181.
- Моисеенко В.М., Орлова Р. В. Адьювантное лечение больных раком ободочной кишки // Практ. онкология. 2000. -1.-е. 19−23.
- Моисеенко В.М., Орлова Р. В. Адьювантное лечение больных раком ободочной кишки. В кн. «Практическая онкология: избранные лекции» под ред. Тюляндина С. А. и Моисеенко В. М. 2004. — с. 214−221.
- Моисеенко В.М., Семенова А. И., Орлова Р. В. Возможности капецитабина в лечении больных распространенными формами солидных опухолей // Вопр. Онкологии. 2001. — Т. 46(1). — с. 112−119.
- Новые цитостатики в лечении злокачественных опухолей. Под ред. Горбуновой В. А. М., — 1998. — 128с. «
- Орлова Р.В. Лекарственное лечение опухолей желудочно-кишечного тракта // Практ. онкол. 2005. — Т.6(1). — с. 33−42.
- Переводчикова Н.И. Химиотерапия метастатического колоректального рака. В кн. «Практическая онкология: избранные лекции» под ред. Тюляндина С. А. и Моисеенко В. М. 2004. — с. 230−244.
- Поддубная И.В. Новые возможности в терапии распространенного колоректального рака. -М., 1999. — с. 15−21.
- Рак ободочной и прямой кишки / Под ред. В. И. Кныша. М., 1997.
- Руководство по химиотерапии опухолевых заболеваний // Под. ред. Н. И. Переводчиковой. -М., 2005. — 698 с.
- Семиглазова Т.Ю., Гершанович М. Л. Пероральный фторпиримидины в химиотерапии злокачественных опухолей // Вопр. Онкологии. — 2001. — Т. 47(4).-с. 388−394.
- Трапезников H.H., Аксель Е. М. Статистика злокачественных новообразований в России и странах СНГ (состояние онкологической помощи, заболеваемость и смертность). М., 2001.
- Тюляндин С.А. Адьювантное лечение рака толстой кишки // Новое в терапии колоректального рака / Под. ред. H.H. Переводчиковой. М., 2001.-с. 74−82.
- Adlard J.W., Richman S.D., Seymour M.T. et al. Prediction of the response of colorectal cancer to systemic therapy // Lancet. 2002. — 3(2). — p. 75−82.
- Adlard J.W., Richman S.D., Seymour M.T., Quirke P. Prediction of the response of colorectal cancer to systemic therapy // Lancet Oncol. 2002. — v.3. — p. 75−82.
- Advanced Colorectal Meta-Analysis Program: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate//J. Clin. Oncol. 1992. — 10. — p. 896−903.
- Ahmed F.Y., Johnston S.J., Cassidy J. et al. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors // J. Clin. Oncol.-1999.-17.-p. 2439.
- Allegra C.J., Parr A.L., Wold L.F. et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer //J. Clin. Oncol. 2002. — 20. — p. 1735−1743.
- Altinbas M., Aykan F.N., Erkisi M. Alternating combination of irinotecan with 5-fluorouracil and folinic acid in first-line chemotherapy of metastatic colorectal cancer // Proc. ASCO. 2002. — 2269.
- Andre B.P., van Kuilenburg. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil // European Journal of Cancer. 2004. -40.-p. 939−950.
- Armand J.P., Boiqe V., Raymond E. et al. Oxaliplatin in colorectal cancer: an overview // Sem. in Oncology. 2000. — 5(10). — p. 96−104.
- Aschele C., Sobrero A., Faderan M.A. et al. Novel mechanisms of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant close schedules // Cancer. Res. 1992. -52.-p. 1855.
- Becouarn Y., Ychore M., Ducreux M. et al. Oxaliplatin (L-OHP) as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients: preliminary activity (toxicity report) // Proc. ASCO. 1997. — 16. — abstr. 804.
- Bosari S., Moneghini L., Graziani D. et al. Bcl-2 oncoprotein in colorectal hyper-plastic polyps, adenomas, and adenocarcinomas // Human Pathology. -1995.-26.-p. 534−540.
- Bosari S., Viale G. The clinical significance of p53 aberrations in human tumours // Virchows Archiv. 1995. — 427. — p. 229−241.
- Broil R., Erdmann H., Duchrow M. et al. Vascular endothelial growth factor VEGF) — a valuable serum tumour marker in patients with colorectal cancer // Eur. J. Surg. Oncol. 2001. — 27. — p. 37−42.
- Chau I., Cunningham D. Adjuvant Chemotherapy in colon cancer: state of the art // Proc. ASCO. 2002. — p. 228−239.
- Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phend-chloroform extraction // Anal. Biochem. -1987.- 162.-p. 156−159.
- Chris Twelwes: Vision of the Future: Capecitabine // The Oncologist. 2001. — 6(suppl.4). — p. 35−39.
- Chu E., Drake J.C., Koeller D.M. et al. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines // Mol. Pharmacol. 1991. — 39. — p. 136−143.
- Clark J. Systemic therapy approaches for colorectal cancer. In «Cancer of the lower gastrointestinal tract» Ed. Willett C.G. 2001. — p. 150−169.
- Cohen A.M., Shank B., Friedman M.A. Colorectal cancer. In «Cancer Principle a Practice of oncology». Eds. De-Vita V.S. et al. 1989. — p. 895 964.
- Colorectal Cancer Collaborative Group Palliative Chemotherapy for advanced colorectal cancer: Systemic review and meta-analysis // Br. Med. J. -2000.-321.-p. 531−535.
- Conti J.A., Kemen M., Saltz L. et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer//Proc. ASCO. 1994. — p. 565.
- Cunningham D., Findlay M. The chemotherapy of colon cancer can no longer be ignored//Eur. J. Cancer. 1995. -29A. -p. 2077−2079.
- Cunningham D., Pyrhonen S., James R.D. A phase III multicenter randomized study of Cpt-11 versus supportive care alone in patients with 5-FU-resistant metastatic colorectal cancer//Proc. ASCO. 1998. — 1.
- Cure H., Chevalier V., Adenis A. et al. Phase II trial of chronomodulated infusion of high-dose fluorouracil and folinic acid in previously untreated patients with metastatic colorectal cancer // J. Clin. Oncol. 2002. — 20. — p. 1175−1181.
- Cynthia Gail Leichman, MD. Molecular Assessment of Response in Colorectal Cancer: A Fork in the Road // ASCO. 2001.
- De Gramont A., Figer A., Seymour M. et al. Leucovorin and fluorouracil with or without Oxaliplatin as first-line treatment in advanced colorectal cancer // J. Clin. Oncol. 2000. — 18, 16. — p. 2938−2947.
- Diasio R.B. Dihydropyrimidine Dehydrogenase (DPD) Deficiency: A 5-Fluorouracil Associated Pharmacogenomic Syndrome // Horizons Cane. Therap. 1998.-4(1). — p. 9−22.
- Diasio R.B., Bravees T.L., Carpenter J.T. Familial deficiency of dihydropyrimidine dehydrogenase: biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity // J. Clin. Invest. -1988.-81.-p. 47−51.
- Diaz-Rubio E., Sastre J., Zanibani A. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study // Ann. Oncol.-1998.-9.-p. 105−108.
- Edler D., Hallstrom M., Johnson P.G. et al. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease free and overall survival in rectal cancer // Clin. Cancer Res., 2000. -6.-p. 1378−1384.
- Elsaleh H., Soontrapornchai P., Griese F. et al. p53 alterations have no prognostic or predictive significance in Dukes' C rectal carcinomas // Int. J. Cancer. 1999. — 15. — p. 1239−1243.
- Etienne M.C., Cheradame S., Fischel J.L. et al. Response to fluorouracil therapy in canecr patients: The role of tumoral dihydropyrimidine dehydrogenase activity//J. Clin. Oncol. 1995. — 13. — p. 1663−1670.
- Etienne M.C., Lagrange J.L., Dassonville O. et al. Population study of dihydropyrimidine dehydrogenase in cancer patients // J. Clin. Oncol. 1994. -12.-p. 2248−2253.
- Ferlay J., Bray F., Pisani P., Parkin D.M. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide // IARC Cancer Base no. 5, version 2.0. Lyon, France: IARC Press, 2004.
- Fisher B. What is early breast cancer // Early breast cancer. Ed. By J. Zander and J. Baltzer. — Berlin etc.: Springer — Verlag. — 1985.
- Fleming R.A., Milano G.A., Gaspard M.Y. et al. Dihydropyrimidine dehydrogenase activity in cancer patients // Eur. J. Cancer. 1993. — 29A. -p. 740−744.
- Folkman J., Watson K., Ingber D. et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia // Nature. 1989. — 339. — p. 58−61.
- Folprecht G., Kohne C.H. The role of new agents in the treatment of colorectal cancer // Oncology. 2004. — v.66. — p. 1−17.
- Fukukawa T., Yoshimura A., Sumizawa T. et al. Angiogenic factor // Nature. 1992.-356.-p. 668.
- Fukushima M., Morita M., Ikeda K. et al. Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors // Int. J. Mol. Med. 2003. — Dec. 12(6). — p. 839−844.
- Gerard B., Bleiberg H., Michel J. et al. Oxaliplatin combinated to 5-FU and folinic acid (5-FU/FA) as second- or third-line treatment in patients with advanced colorectal cancer (CRC) // Proc. ASCO. 1997. — 16. — 228a (suppl.).
- Glazer R.I., Hartman K.D. The effect of 5-fluorouracil on the synthesis and methylation of low molecular weight RNA in L-1210 cells // Med. Pharm. -1980.- 17.-p. 245−249.
- Glimelius B. Palliative treatment of patients with colorectal cancer // Scand. J. Surg. -2003. Vol. 92(1). — p. 74−83.
- Gorlick R., Metzger R., Danenberg K.D. et al. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma // J. Clin. Oncol. 1998. -16. — p. 1465−1469.
- Gray R.G., Barnwell J., Hills R. et al. QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3228 colorectal cancer patients // Proc. ASCO. 2004. — Abstr.3501.
- Graziano F., Casoince S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes’B colorectal cancer patients: how much evidence is enough? // Ann. Oncol. 2003. — 14. — p. 1026−1038.
- Grem J.L. Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin // Semin. Oncol. -1997- 24 (Suppl. 18): c 18−8.
- Grothey A., Jordan K., Kellner O. et al. Randomized phase II trial of capecitabine plus irinotecan vs capecitabine plus oxaliplatin as first line therapy of advanced colorectal cancer // Ann. of Oncology. 2002. — 13. -abstr. 258.
- Hamaji M., Nishida T., Miyazaki S. et al. Dihydropyrimidine dehydrogenase and thymidylate synthase in colon carcinoma // Gan To Kagaku Ry oho. -2002. Jun. 29(6). — p. 889−893.
- Hamilton S.R., Grem J.L. Lowel gastrointestinal cancer // Current Cancer Therapeutics. 1998. — p. 156−164.
- Harris B.E., Carpenter J.T., Diasio R.B. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency // Cancer Res. -1995.-68.-p. 499.
- Harris P.E., Sony R., He Y.J. et al. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase // Biochem. Pharmacol. 1988. — 37. — p. 4759.
- Heggie G.D., Sommadosi J.P., Cross D.S. et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile // Cancer Res. -1987.-47.-p. 2203−2206.
- Holelston R.S. What we could do now: molecular pathology of colorectal cancer // Mol. Pathol. 2001. — Vol. 54. — p. 206−214.
- Houghton J.A., Torrance P.M., Radparvar S. et al. Binding of 5-fluorodeox^uridylate synthase in human colon adenocarcinoma xeno-grafts // Eur. J. Cancer. Clin. Oncol. 1986. — 22. — p. 505.
- Hurwitz H., Franc R.E., Miller H. et al. Bevacizumab plus irinotecan, 5-FU and Leucovorin to the treatment of metastatic CRC: results of randomized phase III trial // New Engl. J. Med. 2004.
- Hurwitz H., Franc R.E., Miller H. et al. Bevacizumab plus irinotecan / 5-FU and leucovorin for the treatment of metastatic CRC: results of a randomized phase HI trial // New. Engl. J. Med. 2004.
- Inokuchi M., Uetake H., Shirota Y. et al. Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis // Cancer Chemother. Pharmaed. 2004. — May. 53(5). — p. 391 396.
- Ionov Y., Peinado M.A., Malkhosyan S. et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic tumorigenesis //Nature. 1993. -363. — p. 558−561.
- Ishitsuka H., Miwa M., Ishikawa T. et al. Capecitabine: an orally available fluoropyrimidine with tumor selectivity // Proc. Am. Assos. Cancer REs. -1995.-36.-2426a.
- Jiang L.N., Yu S.Y., Xiong H.H. et al. Expression of thymidine Phosphorylase in cancer // Zhonghua Zhong Liu Za Zhi. 2004. — May, 26(5). — p. 297−299. Chinese.
- Johnston P.G., Fisher E.R., Rockette H.E. et al. The role of thymidylate synthase expression and outcome of adjuvant chemotherapy in patients with rectal cancer//J. Clin. Oncol. 1994. — 12. — p. 2640−2647.
- Johnston P.G., Lenz H.J., Leichman C.G. et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors // Cancer Res. 1995. -55. — p. 1407−1412.
- Johnston P.G., Liapg C.M., Henry S. et al. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue // Cancer Res. 1991. — 24. — p. 66 686 676.
- Johnston S.J., Ridge S.A., Cassidy J. et al. Regulation of Dihydropyrimidine Dehydrogenase in Colorectal Cancer // Clinical Cancer Research. 1999. — 5. -p. 2566−2570.
- Kabbinavar F., Glimelius B., Barnwell J. et al. Phase II randomized trial comparing Bevacizumab plus fluorouracil / leucovorin with fluorouracil / leucovorin alone in patients with metastatic colorectal cancer // J. Clin. Oncol. -2003.-p. 2160−2165.
- Kahlenberg M.S., Stoler D.L., Rodrigues-Bigas M.A. et al. p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma // Cancer. 2000. — 88(8). — p. 1814−1819.
- Kahlenberg M.S., Sullivan J.M., Witmer D.D. et al. Molecular prognostics in colorectal cancer // Surgical Oncology. — 2003. 12. — p. 173−186.
- Kerr D.J., Middgley R. New colorectal cancer drugs with novel mechanisms of action // 3rd International conference Perspective in colorectal cancer. -Dublin.-2001.-105.
- Kitazono M., Takebayashi Y., Ishitsuka K. et al. Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase // Biochem. Biophys. Res. Commun. 1998. — 253. — p. 797−803.
- Koch M., McPherson T.A., Egedahl R.D. Effect of sex and reproductive history on the survival of patients with colorectal cancer // J. Chronic. Dis. -1982.-35.-p. 69−72.
- Kondo Y., Takemiya S., Sakamoto J. et al. A multicenter phasw II trial of capecitabine in previously untreated advanced metastatic colorectal cancer // Proc. ASCO. 2002. — 2322.
- Kubiak R., Miszczak., Zaborzska et al. The activity of thymidine phosphorylase correlates with tumor size and lymph nodes status in breast carcinoma //Naturforsch. 1999. — p. 1096−1102.
- Kumar H., Heer K., Lee P.W. et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer // Clinical Cancer Research. 1998. — 4. — p. 1279−1285.
- Landis S.H., Murray T., Bolden S. et al. Cancer statistics. 1999. CA // Cancer J. Clin.- 1999.-49.-p. 8−31.
- Landis S.M., Murray T., Bolden S. et al. Cancer statistics 1999 // Ca. 1999. -49.-p. 8−31.
- Lee J., Kim T., Kim D. et al. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil / leucovorin chemotherapy // ASCO. 2003. — abstr.1425.
- Leichman C.G. Molecular Assessment of Response in Colorectal Cancer: A Fork in the Road // Proc. ASCO. 2001. — p. 317−332.
- Leichman C.G., Fleming T.R., Muggia C.M. et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study //J. Clin. Oncol. 1995. — 13. — p. 1303.
- Lenz H.J., Hayashi K., Salonga D. et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival // Clin. Cancer. Res. 1998. — 4. — p. 1243−1250.
- Lenz H.J., Mayer R.J., Gold P.J. et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin // Proc. ASCO. 2004. — Abstr. 3510.
- Lincoln D.W., Hrushesky W.J., Wood P.A. Circadian organization of thymidylate synthase activity in normal tissues: A possible basis for 5-fluorouracil chronotherapeutic advantage // Int. J. Cancer. 2000. — 88. — p. 479−485.
- Liu B., Parsons R., Papadopoulos N. et al. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients // Nature. 1996. — 2. -p. 169−174.
- Lu Z.H., Zhang R., Diasio R.B. Purification and characterization of dihydropyrimidine dehydrogenase from human liver // J. Biol. Chem. 1992. -263. — p. 17 102−17 109.
- Maeda K., Chung Y., Kany S. et al. Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma // Int. J. Cancer. 1997. -74. — p. 310−315.
- Marchetti S., Chazai M., Dubreuil A., et al. Impact of thymidine phosphorylase superexpression on fluoropyrimidine activity and on tumor angiogenesis //British Journal of Cancer. 2001. — 85(3). — p. 439−445.
- Matsuura T., Kuratate I., Teramachi K. et al. Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas // Cancer Res. 1999. -59. — p. 5037−5040.
- Matsuura T., Kuratate L, Teramachi K. et al. Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas // Cancer. Res. 1999. -59.-p. 5037−5040.
- Mayer R.J., O’Connell M.J., Tepper J.F., Wolmark N. Status of adjuvant therapy for colorectal cancer // J. Nat. Cane. Inst. 1989. — 81. — p. 1359.
- Mayer R.J., Stablein D.M. Adjuvant colon cancer trials of the Gastrointestinal Tumor Study Group. In «NTH Consensus Development Conference. Adjuvant Therapy for patients with colon and rectum cancer». 1990. — p. 35−40.
- Mayer S. et al. Tomudex (Raltitrexed) plus 5-FU combination treatment for patients with advanced colorectal cancer: A Phase I study // Eur. Jour, of Cancer. 1999. — 35. — p. 74.
- Meyerhardt J.A., Mayer R.J. Systemic therapy for colorectal cancer // New. Engl. J. Med. 2005. — 352. — p. 476−487.
- Midgley R., Kerr D. Colorectal cancer. 1999. — 353. — p. 391−399.
- Milano G., Etienne M.C. Individualizing therapy with 5-fluorouraeil related to dihydropyrimidine dehydrogenase: theory and limits // Ther. Drug Monit. — 1996.- 18.-p. 335−340.
- Moertel C., Fleming T., MacDonald J. et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage II colon carcinoma: A final report//Ann. Int. Med. 1995. — 122. — p. 321−326.
- Moertel C.G. Chemotherapy for colorectal cancer // N. Eng. J. Med. 1994. -330.-p. 1136−1143.
- Mori K., Hasegawa M., Nishida M. et al. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues // Int. J. Oncol. 2000. — 7. — p. 33−38.
- Naguib FNM, EI Kouni AM, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues // Cancer Res. 1985. — 45. — p. 56 405−56 412.
- National Institutes of Health Consensus Conference Adjuvant Therapy for patients with colon and rectal cancer // JAMA. 1990. — 264. — p. 1444−1450.
- Obrand D.I., Gordon P.H. Incidence and patterns of recurrence following curative resection for colorectal carcinoma // Dis. Colon. Rectum. 1997. — 40.-p. 15−24.
- Ogura E., Senzaki H., Yamamoto D. et al. Prognostic significance of bcl-2, bcl-xL/S, bax and bax expression in colorectal carcinomas // Oncol. Rep. -1999.-6(2).-p. 365−369.
- Oi K., Makino M., Ozaki M. et al. Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes’C colorectal cancer // Anticancer Res. 2004. — Jan-Feb. 24(1). — p. 273−279.
- Okonkwo A., Musunuri S., Talamonti M. et al. Molecular markers and prediction of response to chemoradiation in rectal cancer // Oncology Reports. -2001.-8.-497−500.
- Okonkwo A., Musunuri S., Talamonti M. et al. Molecular markers and prediction of response to chemoradiation in rectal cancer // Oncology reports. -2001.-8.-p. 497−500.
- Palmqvist R., Sellberg P., Oberg A. et al. Low tumour cell proliferation of the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers // Br. J. Cancer. 1999. — 79. — p. 577−581.
- Paradiso A.V., Maiello E., Renieri G. et al. Topoisomerase-I (Topo-I) and Thymidylate Synthase (TS) primary tumor expression are predictive of response to CPT-11 in advanced colorectal cancer (CRC) patients // Proc. ASCO. -2001. -20. Abstr. 599.
- Park D.J., Soehlmacher J., Zhony W. et al. Human thymidylate synthase gene polymorphism determines response to capecitabine chemotherapy in advanced colorectal cancer // Proc. ASCO. 2001. — Abstr. 514.
- Parker W.B., Cheng Y.C. Metabolism and mechanism of action of 5-fluorouracil // Pharmacol. Ther. 1990. — 48. — p. 381−395.
- Parkin D.M., Pisani P., Ferlay J. Global cancer statistics // Ca. 1999. — 49. -p.33.
- Pasche B., Mulcahy M., Benson A.B. et al. Molecular markers in prognosis of colorectal cancer and prediction of response to treatment // Best. Pract. Res. Clin. Gastroenterol. 2002. — v. 16. — p. 331−345.
- Pasche B., Mulcahy M., Benson A.B. et al. Molecular markers in prognosis of colorectal cancer and prediction of response to treatment // Best. Practice and Research Clinical Gastroenterology. 2002. — 16(2). — p. 331−345.
- Peters G.J., Pinedo H.M., Fuwerda W. et al. Do antimetabolites interfere with the glucosylation of cellular glycoconjugates? // Eur. J. Cancer. 1990. — 26. -p. 516−523.
- Peters G.J., van Groeningen C.J., van der Wilf C.L. et al. Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin // Semin. Oncol. 1992. — 19. — p. 26−35.
- Rothenberg M.L., Eckarolt J.R., Burns H.A. et al. Irinotecan as second-line therapy for patients with 5-FU-refractory colorectal cancer // Proc. ASCO. -1994. p. 578.
- Rustum Y.M. Modulation of fluoropyrimidines by leucovorin: rational and status // J. Surg. Oncol. 1991. — 2 (116). — p. 123.
- Saltz L.B., Douillard J.Y., Pirotta N. et al. Irinotecan plus fluorouracil, leucovorin for metastatic colorectal cancer: a new survival standart // Oncologist. 2001. — 6. — p. 81−91.
- Santi D.V., McHenry C.S., Sommer A. Mechanisms of interactions of thymidylate synthetase with 5-fluorodeoxyuridylate // Biochem. — 1974. 13. p. 471.
- Sawada N., Ishikawa T., Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol (Taxoter) in human cancer xenografts // Clin. Cancer Res. 1998. — 4. — p. 1013−1021.
- Sawada N., Ishikawa T., sekiguchi F. et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts // Clin. Cancer Res. 1999. — 5. — p. 2948−2953.
- Sawada T., Hirakawa K., Shirao K. et al. Confirmatory phase II study and final results of S-l in patients with metastatic colorectal cancer in Japan // Proc. ASCO. 2002. — Abstr. 2223.
- Sawyer R.C., Stolfi R.I., Martin D.C. et al. Incorporation of 5-fluorouracil into murine bone marrow DNA in vivo // Cane. Res. 1984. — 44. — p. 18 471 851.
- Scheithauer W., Rosen H., Kornek G.V. et al. Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer // Br. Med. J. 1993. — 306. — p. 752−755.
- Schrag D., Weeks J. Costs and cost-effectiveness of colorectal cancer prevention and therapy // Semin. Oncol. 1999. — 26. — p. 561−568.
- Schuctz J.D., Collins J.M., Wallace H.J. et al. Alteration of the secondary structure of newly synthesized DNA from murine bone marrow cells by 5-fluorpuracil // Cancer Res. 1986. — 46. — p. 119−123.
- Schuller J., Reigner B.G., Durston S. et al. Tumor selectivity of Xeloda in colorectal cancer patients // Proc. ASCO. 1997. — 16. — 797a.
- Schwartz E.L., Baptist E., Walder S. et al. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cell to 5-fluorouracil // J. Biol. Chem. 1995. — 11. — p. 19 073−19 077.
- Shan A., MacDonald W., Goldie J. et al. 5-FU infussion in advanced colorectal cancer. A comparison of three dose schedules // Cane. Treat. Rep. -1985.-69.-p. 739.
- Shirota Y., Stochlmacher J., Brabender J. et al. ERCC 1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy // J. Clin. Oncol. -2001. 19. — p. 4298−4304.
- Simmonds P. Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis // Br. Med. J. 2000. — 321. — p. 531 535.
- Smith D.R., Ji C.V., Goh H.S. et al. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas // Br. J. Cancer.1996.-74.-p. 216−223.
- Sobrero A.F., Aschele C., Bertino J.R. Flurouracil in colorectal cancer a tale of two drugs: Implication for biochemical modulation // J. Clin. Oncol.1997.-15.-p. 368−381.
- Specht K., Richter T., Muller U. et al. Quantitative gene expression analysis in microdissected archival formalin-fized and paraffin-embedded tumor tissue //Am. J. Pathol. -2001. 158. -p. 419−429.
- Speyer J.C., Hochster H., Chachoua A. et al. A phase I/II study of eniluracil / 5-fluorouracil plus oxaliplatin in patients with pre-treated colorectal cancer // Proc. ASCO. -2001 Abstr. 574.
- Sumizawa T., Fukukawa T., Haraguchi M. et al. Thymidine Phosphorylase activity associated with platelet-derived endothelial cell growth factor // J. Biochem. 1993. — 114. — p. 9−14.
- Taguchi T., Horikoshi N., Mitachi Y. et al. Clinical evaluation of S-l in patients with advanced gastrointestinal cancer // Proc. 7th Intern. Cong. Anti-Canc. Treatm. 1997. — 87.
- Takahashi Y., Kitadai Y., Bucana C.D. et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer // Cancer Res. 1995. -55.-p. 3964−3968.
- Takahashi Y., Tucker S.L., Kitadai Y. et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer//Arch. Surg. 1997. — 132. -p. 541−546.
- Takebayashi Y., Akiyama S-L, Akiba S. et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine Phosphorylase, in human colorectal carcinoma // J. Natl. Cancer Inst. 1996. — 88. — p. 11 101 117.
- Takebayashi Y., Yamada K., Marugama I. et al. The expression of thymidine Phosphorylase and thrombomodulin in human colorectal carcinomas // Cancer Lett. 1995. -25. p. 1−7.
- Toffoli G., Cecchin E. Pharmacogenetics of stomach cancer // Suppl. Tumori. 2003. — Vol. 2(5). — p. 19−22.
- Trancini G., Petrioli R., Lorenzini L. et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer // Gastroenter. 1994. — 106. — p. 899−906.
- Tsuji T., Sawai T., Takeshita H. et al. Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer // Cancer Chemother. Pharmaed. 2004. — Aug. 10.
- Tubiana M. The scientific bases of cancer management: at the interface between fundamental research and clinical practice // J. Cancer Res. — 1991. — 117.-p. 275.
- Vaux D.L., Aguila H.L., Weissman I.L. et al. Bcl-2 prevents death of factor-deprived cells but fails to prevent apoptosis in targets of cell mediated killing // Int. Immunol. 1992. — 4. — p. 821−824.
- Vogel I., Soeth E., Ruder C. et al. Disseminated Tumor cells in the blood and/or bone marrow of patients with colorectal carcinoma are an independent prognostic factor // Ann. Oncol. 2000. — 11. — Abstr. 183.
- Walton M.I., Whysony D., O’Connor P.M. et al. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptotherin induced apoptosis // Cancer Res. 1993. — 53. — p. 1853−1861.
- Washtein W.L. Increased levels of thymidylate synthase in cells exposed to 5-fluorouracil // Mol. Pharmacol. 1987. — 28. — p. 461−467.
- Werther K. et al. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma // Br. J. Cancer. -2002. -Feb, l. 86(3). — p. 417−423.
- Wolmark N. et al. The relative efficacy of 5-FU+leucovorin, 5-FU+levamisole and 5-FU+leucovorin+levamisole inpatients with Duke’s B and C carcinoma of the colon: first report of NS-ABD C-04 // Proc. Of ASCO. 1996. -p.205 (abstr. 460).
- Wolmark N., Rockette H., Fisher B. et al. The benefit of leucovorin-modulated fluorouracil for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03 // J. Clin. Oncol. -1993.- 11.-p. 1979−1987.
- Xiao J.X., Sun H., Yany J. et al. Expression of thymidine phosphorylase in human colorectal carcinoma and it’s clinical significance // Ai Zheng. 2004. -23(3).-p. 303−305.
- Yamachika T., Nakanishi H., Inada K. et al. A new prognostic factor for colorectal carcinoma. Thymidylate synthase and it’s therapeutic significance // Cancer. 1998. — 1(82). — p. 70−77.